Antonio P. Guerra

Learn More
AIM Psoriasis is a common, chronic, immune-mediated skin disorder that may be complicated by psoriatic arthritis in up to one-third of patients. Psoriasis treatments are increasingly effective, yet more expensive, thus requiring rational decision-making on interventional priorities. The ability to perform cost-utility analyses is hindered by the lack of(More)
Scalone and Cortesi [1] point out that our paper does not mention the social tariffs used to convert EQ-5D-3L into quality-adjusted life-years (QALYs). The answer is straightforward: we applied the UK social tariffs—those most employed in Italy at the time of our research. Indeed, just a few months before our paper was published, Scalone et al. [2](More)
Psoriasis is a common chronic inflammatory disease affecting the skin and joints. Moderate to severe psoriasis is traditionally treated with systemic treatments, which can be effective but are often associated with relevant adverse effects, even when administered intermittently or rotationally. Biologic therapies may provide high and consistent efficacy(More)
  • 1